| | A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter . . . |
Pending |
30 Mar 2021 |
| | A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabe . . . |
Completed |
23 Sep 2019 |
| | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients wi . . . |
Ongoing |
03 Jul 2020 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
30 Mar 2021 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
31 Mar 2021 |
| | A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metasta . . . |
Ongoing |
09 Sep 2020 |
| | A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose,Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Patients with Schizophrenia, Followe . . . |
Ongoing |
07 Oct 2021 |
| | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab . . . |
Ongoing |
10 Oct 2019 |
| | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older. . . . |
Ongoing |
25 Jan 2021 |
| | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in Asian subjects (≥16 to 80 years of age) with parti . . . |
Ongoing |
12 Aug 2021 |
| | A randomized, double-blind, placebo-controlled, parallel group, multi-center trial of pregabalin as adjunctive therapy in pediatric and adult subjects with primary generalized tonic-clonic seizures . . . |
Completed |
17 Jul 2019 |
| | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as Add on to Standard of Care in Adult Subjects With COVID-19 . . . |
Ongoing |
30 Nov -0001 |
| | A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerabilit . . . |
Ongoing |
30 Jul 2020 |
| | A Randomized, Double-blind, Placebo-controlled, Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetic Profiles and Immunogenecity of JS016 (Recombinant Human Anti-SA . . . |
Completed |
08 Oct 2021 |
| | A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subject . . . |
Pending |
07 Oct 2021 |
| | A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo with Chemotherapy . . . |
Terminated |
19 Jul 2021 |
| | A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10to . . . |
Ongoing |
14 Aug 2020 |
| | A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic L . . . |
Pending |
12 May 2020 |
| | A randomized, observer blinded, controlled trial to evaluate the safety and immunogenicity of a new formulation of Euvichol® (killed bivalent (O1 and O139) whole cell oral cholera vaccine (WC-OCV) ma . . . |
Completed |
22 Apr 2019 |
| | A Randomized, Open Label Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) versus Intravenous Methotrexate in Patients with Recurrent and/or Metastatic Head and Neck Squ . . . |
Completed |
01 Jul 2019 |
| | A Randomized, Placebo-Controlled Phase I/IIa Study to Evaluate the Safety, Tolerability, and Efficacy of PG04 Ointment in Subjects Colonized with Staphylococcus aureus . . . |
Completed |
06 Oct 2021 |
| | A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma . . . |
Ongoing |
26 Nov 2020 |
| | A Study of Guselkumab in Participants with Active Psoriatic Arthritis |
Ongoing |
11 Oct 2021 |
| | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) . . . |
Ongoing |
09 Jul 2021 |
| | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and L . . . |
Pending |
11 Sep 2021 |